Roche aims to bolster breast cancer pipeline with early-stage Astex deal

July 6, 2026 10:53 AM EDT DealsPharma Roche's $25M As­tex deal is small mon­ey up­front, but a big sig­nal for breast can­cer goals Elizabeth Cairns Senior biopharma journalist Mon­day’s deal be­tween Ot­su­ka’s sub­sidiary As­tex and Roche’s sub­sidiary Genen­tech is of in­ter­est not be­cause it is big mon­ey — the up­front fee is just $25 … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER